British drug giant AstraZeneca is rushing forward a big clinical trial for its blood cancer drug Calquence because it has shown early promising results in later-stage COVID-19 patients—those in intensive care units and on ventilators. Calquence and top-selling leukemia drug Imbruvica are the latest hopes in getting coronavirus patients off ventilators, where there is a 50% mortality rate.
{iframe}https://www.forbes.com/sites/nathanvardi/2020/04/13/exclusive-astrazenecas-calquence-shows-early-promise-for-covid-19-patients/#7fded4854677{/iframe}